FDA制剂厂检查指南.docx
- 文档编号:12596217
- 上传时间:2023-04-20
- 格式:DOCX
- 页数:45
- 大小:31.91KB
FDA制剂厂检查指南.docx
《FDA制剂厂检查指南.docx》由会员分享,可在线阅读,更多相关《FDA制剂厂检查指南.docx(45页珍藏版)》请在冰豆网上搜索。
FDA制剂厂检查指南
GUIDETOINSPECTIONSOF
DOSAGEFORMDRUGMANUFACTURER'S-CGMPR'S
Note:
ThisdocumentisreferencematerialforinvestigatorsandotherFDApersonnel.ThedocumentdoesnotbindFDA,anddoesnoconferanyrights,privileges,benefits,orimmunitiesfororonanyperson(s).
I.INTRODUCTION
ThisdocumentisintendedtobeageneralguidetoinspectionsofdrugmanufacturerstodeterminetheircompliancewiththedrugCGMPR's.ThisguideshouldbeusedwithinstructionsintheIOM,otherdruginspectionguides,andcomplianceprograms.AlistoftheinspectionguidesisreferencedinChapter10oftheIOM.Someoftheseguidesare:
◆GuidetoInspectionsofBulkPharmaceuticalChemicals.
◆GuidetoInspectionsofHighPurityWaterSystems.
◆GuidetoInspectionsofPharmaceuticalQualityControlLaboratories.
◆GuidetoInspectionsofMicrobiologicalPharmaceuticalQualityControlLaboratories.
◆GuidetoInspectionsofLyophilizationofParenterals.
◆GuidetoInspectionsofValidationofCleaningProcesses.
◆GuidetoInspectionsofComputerizedSystemsinDrugProcessing.
◆GuidelineonGeneralPrinciplesofProcessValidation.
II.CURRENTGOODMANUFACTURINGPRACTICEREGULATIONS
Prescriptionvs.Non-prescription
AlldrugsmustbemanufacturedinaccordancewiththecurrentgoodmanufacturingpracticeregulationsotherwisetheyareconsideredtobeadulteratedwithinthemeaningoftheFD&CAct,Section501(a)
(2)(B).
RecordsrelatingtoprescriptiondrugsmustbereadilyavailableforreviewinaccordancewithSec.704(a)
(1)(B)oftheFD&CAct.IftheproductisanOTCdrugwhichiscoveredbyanNDAorANDA,FDAmayreview,copyandverifytherecordsunderSec.505(k)
(2)oftheFD&CAct.However,iftheproductisanOTCdrugforwhichthereisnoapplicationfiledwithFDA,thefirmisnotlegallyrequiredtoshowtheserecordstotheinvestigatorduringaninspectionbeingconductedunderSection704oftheFD&CAct.Nonetheless,allmanufacturersofprescriptionandOTCdrugsmustcomplywiththedrug
CGMPRrequirements,includingthoseinvolvingrecords.Theinvestigatorshouldreviewtheserecordsaspartoftheinspectionindeterminingthefirm'scompliancewiththeCGMPregulations.Onrareoccasions,afirmmayrefusetoallowreviewofOTCrecordsstatingtheyarenotlegallyrequiredto.Whilethefirmmaybeundernolegalobligationtopermitreviewofsuchrecords,thisdoesnotrelievethefirmofitsstatutoryrequirementtocomplywiththegoodmanufacturingpracticesundersection501(a)
(2)(B)oftheFoodDrugandCosmeticAct,includingtherequirementsformaintainingrecords.
IfafirmrefusesreviewofOTCrecords,theinvestigatorshoulddeterminebyotherinspectionalmeanstheextentofthefirm'scompliancewithCGMPR's.InspectionalobservationsandfindingsthatCGMPR'sarenotbeingfollowedaretobecitedonaListofInspectionalObservations,FDA-483,forbothprescriptionandnon-prescriptiondrugs.
OrganizationandPersonnel[21CFR211SubpartB]
ThefirmmusthaveaqualitycontroldepartmentthathastheresponsibilityandauthorityasdescribedinthereferencedCFR.Thequalitycontroldepartmentmustmaintainitsindependencefromtheproductiondepartment,anditsresponsibilitiesmustbeinwriting.
Obtainthename,titleandindividualresponsibilitiesofcorporateofficersandotherkeyemployeesasindicatedintheIOM.
Inthedrugindustry,anemployee'seducationandtrainingfortheirpositionhasasignificantimpactontheproductionofaqualityproduct.
Reportwhetherthefirmhasaformalizedtrainingprogram,anddescribethetypeoftrainingreceived.Thetrainingreceivedbyanemployeeshouldbedocumented.
Qualitycontrolmustdoproductannualreviewoneachdrugmanufactured,andhavewrittenannualreviewprocedures.Reviewthesereportsindetail.Thisreportwillquicklyletyouknowifthemanufacturingprocessisundercontrol.Thereportshouldprovideasummaryalllotsthatfailedin-processorfinishedproducttesting,andothercriticalfactors.Investigateanyfailures.
Qualitycontrolmustvalidatethemanufacturingprocessforeachdrugmanufactured.Reviewandevaluatethisdata.
BuildingsandFacilities[21CFR211SubpartC]
Reviewtheconstruction,size,andlocationofplantinrelationtosurroundings.Theremustbeadequatelighting,ventilation,screening,andproperphysicalbarriersforalloperationsincludingdust,temperature,humidity,andbacteriologicalcontrols.Theremustbeadequateblueprintswhichdescribethehighpuritywater,HEPA,andcompressedairsystems.Thesitemusthaveadequatelocker,toilet,andhandwashingfacilities.
Thefirmmustprovideadequatespacefortheplacementofequipmentandmaterialstopreventmix-upsinthefollowingoperations:
◆receiving,sampling,andstorageofrawmaterials;
◆manufacturingorprocessing;
◆packagingandlabeling;
◆storageforcontainers,packagingmaterials,labeling,andfinishedproducts;
◆productionandcontrollaboratories.
Equipment[21CFR211SubpartD]
Reviewthedesign,capacity,construction,andlocationofequipmentusedinthemanufacturing,processing,packaging,labeling,andlaboratories.
Describethemanufacturingequipmentincludingbriefdescriptionsofoperatingprinciples.Considertheuseofphotographs,flowcharts,anddiagramstosupplementwrittendescriptions.
Newequipmentmustbeproperlyinstalled,andoperateasdesigned.DetermineiftheequipmentchangewouldrequireFDApre-approvaland/orrevalidationofthemanufacturingprocess.Theequipmentmustbecleanedbeforeuseaccordingtowrittenprocedures.Thecleaningmustbedocumentedandvalidated.
Theequipmentshouldnotadverselyeffecttheidentity,strength,quality,orpurityofthedrug.Thematerialusedtomanufacturetheequipmentmustnotreactwiththedrug.Also,lubricantsorcoolantsmustnotcontaminatethedrug.
Theequipmentshouldbeconstructedandlocatedtoeasecleaning,adjustments,andmaintenance.Also,itshouldpreventcontaminationfromotherorpreviousmanufacturingoperations.Equipmentmustbeidentifiedastoitscleaningstatusandcontent.Thecleaningandmaintenanceoftheequipmentareusuallydocumentedinalogbookmaintainedintheimmediatearea.Determineiftheequipmentisofsuitablecapacityandaccuracyforuseinmeasuring,weighing,ormixingoperations.Iftheequipmentrequirescalibration,theymusthaveawrittenprocedureforcalibratingtheequipmentanddocumentthecalibration.
ComponentsandProductContainers[21CFR211SubpartE]
Inspectthewarehouseanddeterminehowcomponents,drugproductcontainers,
andclosuresarereceived,identified,stored,handled,sampled,tested,and
approvedorrejected.Theymusthavewrittenprocedureswhichdescribehow
theseoperationsaredone.Challengethesystemtodecideifitis
functioningcorrectly.Ifthehandlingandstorageofcomponentsare
computercontrolled,theprogrammustbevalidated.
Thereceivingrecordsmustprovidetraceabilitytothecomponent
manufacturerandsupplier.Thereceivingrecordsforcomponentsshould
containthenameofthecomponent,manufacturer,supplierifdifferentfrom
themanufacturer,andcarrier.Inaddition,itshouldincludethereceiving
date,manufacturer'slotnumber,quantityreceived,andcontrolnumber
assignedbythefirm.
Checksanitaryconditionsinthestoragearea,stockrotationpractices,
retestdates,andspecialstorageconditions(protectionfromlight,
moisture,temperature,air,etc.).Inspectglandularandbotanical
componentsforinsectinfestation.
Componentsorfinishedproductadulteratedbyrodents,insects,orchemicals
mustbedocumentedandsubmittedforseizure.
Collecttheevidenceevenifthefirmplanstovoluntarilydestroythe
product.Bealertforcomponents,colors,andfoodadditivesthatmaybenew
drugsubstances,appeartohavenouseintheplantorappeartobefroman
unknownsupplier.CheckthecolorsagainsttheColorAdditivesStatusList
intheIOMDetermineifthecolorisapprovedforitsintendeduse,and
requiredstatementsaredeclaredonthedruglabel.
Componentsmightbereceivedatmorethanonelocation.Componentsmustbe
handledinaccordancewiththedrugCGMP'sincludingcomponentsusedinthe
researchanddevelopmentlab.Determinehowcomponentsareidentifiedafter
receiptandquarantineduntilreleased.Componentsmustbeidentifiedsothe
status(quarantine,approved,orrejected)isknown.Reviewthecriteriafor
removingcomponentsfromquarantineandchallengethesystem.Determinewhat
recordsaremaintainedinthestorageareatodocumentthemovementof
componentstootherareas,andhowrejectedcomponentshandled.The
componentcontainerhasanidentificationcodeaffixedtoit.Thisunique
codeprovidestraceabilityfromthecomponentmanufacturertoitsuseinthe
finishedproduct.
Reviewthesamplingandtestingproceduresforcomponents,andtheprocess
bywhichapprovedmaterialsarereleasedforuse.Decideifthesepractices
areadequateandfollowed.
Determinethevalidity,andaccuracyofthefirm'sinventorysystemfordrug
components,containers,closuresandlabeling.Challengethecomponent
inventoryrecordsbyweighingalotandcomparingtheresultsagainstthe
quantityremainingontheinventoryrecord.Significantdiscrepanciesin
theserecordsshouldbeinvestigated.
Evaluatethefollowingtodeterminewhetherthefirmhasshownthatthe
containersandclosuresarecompatiblewiththeproduct,willprovide
adequateprotectionforthedrugagainstdeteriorationorcontamination,are
notadditiveorabsorptive,andaresu
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- FDA 制剂 检查 指南